Skip to main content

Table 3 Risk analysis for non-CR, non-CC, and non-TC during the overall study period

From: Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials

  Univariable analysis Multivariable analysis
  OR 95% CI P value OR 95% CI P value
A: non-CR
 Sex (female vs male) 4.59 1.26–16.78 0.021 2.50 0.54–11.63 0.241
 Age (< 60 years vs > =60 years) 4.24 1.49–12.09 0.007 2.40 0.69–8.37 0.169
 NK1RA inclusive regimen (yes vs no) 2.89 0.79–10.58 0.110 1.43 0.33–6.14 0.628
 CBDCA dose (6 vs 4–5) 2.44 0.81–7.34 0.113    
 Habitual alcohol consumption (yes vs no) 0.35 0.09–1.27 0.110    
 Motion sickness (yes vs no) 1.34 0.48–3.72 0.571    
 Morning sickness (yes vs no) 2.16 0.65–7.15 0.206    
B: non-CC       
 Sex (female vs male) 3.69 1.16–11.76 0.027 1.78 0.43–7.37 0.430
 Age (< 60 years vs > =60 years) 4.17 1.53–11.34 0.005 2.54 0.75–8.55 0.134
 NK1RA inclusive regimen (yes vs no) 3.39 0.94–12.25 0.063 1.89 0.46–7.78 0.378
 CBDCA dose (6 vs 4–5) 2.20 0.79–6.18 0.133    
 Habitual alcohol consumption (yes vs no) 0.30 0.08–1.07 0.063    
 Motion sickness (yes vs no) 1.07 0.40–2.85 0.894    
 Morning sickness (yes vs no) 1.48 0.49–4.46 0.483    
C: non-TC
 Sex (female vs male) 3.77 1.62–8.76 0.002 1.69 0.60–4.76 0.323
 Age (< 60 years vs > =60 years) 5.06 2.26–11.33 < 0.001 3.08 1.17–8.12 0.023
 NK1RA inclusive regimen (yes vs no) 3.23 1.30–8.01 0.012 1.47 0.49–4.46 0.492
 ECOG PS (0–1 vs 2) 2.73 0.32–22.93 0.356    
 CBDCA dose (6 vs 4–5) 2.54 1.15–5.57 0.021 1.46 0.57–3.72 0.431
 Habitual alcohol consumption (yes vs no) 0.66 0.29–1.47 0.310    
 Motion sickness (yes vs no) 0.69 0.32–1.49 0.340    
 Morning sickness (yes vs no) 1.62 0.69–3.77 0.264    
  1. OR odds ratio; CI confidence interval; CR complete response; CC complete control; TC total control; CBDCA carboplatin; ECOG PS Eastern Cooperative Oncology Group performance status.